Aquapheresis

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024
Diuretic, Ultrafiltration, Hospital, Section, Artificial intelligence, Randomized controlled trial, Mount Sinai Health System, Quality of life, Acute decompensated heart failure, Hierarchy, Aquapheresis, Valvular heart disease, Risk, Heart failure, Arrhythmia, AUF, ALD, History, Yale School of Medicine, Patient, HF, Machine learning, Cerebrovascular disease, THT, Mortality, Roflumilast, Pharmaceutical industry

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Retrieved on: 
Tuesday, February 6, 2024
ICU, Diuretic, Mount Sinai Hospital, Patient, Cirrhosis, Ascites, FDA, Peritoneal cavity, Aquapheresis, Literature review, Food, Blood, Paracentesis, Series, Liver disease, Blood volume, Medical imaging

The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .

Key Points: 
  • The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .
  • The most common cause of liver disease was alcohol-related, with nine of the 14 patients presenting with alcohol-associated cirrhosis.
  • In this case series, Aquadex was shown to provide a potential additional solution to mitigate these clinical gaps.
  • Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics.

The Portability of Aquadex SmartFlow® from CHF Solutions Could Mean More Critically-Ill Patients Have Access to Life-Saving Ultrafiltration Therapy

Retrieved on: 
Thursday, April 8, 2021
Medicine, Clinical medicine, Branches of biology, Aquapheresis, Ultrafiltration, Hypervolemia, Kidney, Blood, Membrane technology

New evidence demonstrates that ultrafiltration therapy (aquapheresis) using the Aquadex SmartFlow system by CHF Solutions may be lifesaving for patients with profound and catastrophic multi-organ failure due to fluid overload, in part due to the devices flexibility and portability.

Key Points: 
  • New evidence demonstrates that ultrafiltration therapy (aquapheresis) using the Aquadex SmartFlow system by CHF Solutions may be lifesaving for patients with profound and catastrophic multi-organ failure due to fluid overload, in part due to the devices flexibility and portability.
  • Aquadex gently removes excess fluid from the blood to alleviate burden on key organs such as the kidneys and heart.
  • Aquadex therapy was used to remove excess fluid in concert with other life-saving therapies during a >3-hour transit and subsequent surgery to repair the heart.
  • The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy.

ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Clinical medicine, Medicine, Hypervolemia, Ultrafiltration, Kidney, Membrane technology, Aquapheresis, Renal dialysis, Dialysis

He will discuss the morbidity and mortality issues surrounding fluid overload in patients undergoing cardiac surgery, the cardio-renal connection, and how to best manage these patients.

Key Points: 
  • He will discuss the morbidity and mortality issues surrounding fluid overload in patients undergoing cardiac surgery, the cardio-renal connection, and how to best manage these patients.
  • Fluid overload is extremely common after cardiac procedures and can lead to ongoing cardio-renal complications.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.
  • The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload).

CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients

Retrieved on: 
Thursday, January 21, 2021
Finance, Banks, Hypervolemia, Financial services, Ultrafiltration, Fluid mechanics, UBS, Aquapheresis

CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.

Key Points: 
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.
  • CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland.
  • The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload).
  • CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF

Retrieved on: 
Tuesday, December 15, 2020
Anatomy, Branches of biology, Heart diseases, Organ failure, Clinical medicine, Acute decompensated heart failure, Ultrafiltration, Hypervolemia, Heart failure, Diuretic, Aquapheresis, Management of heart failure

1

Key Points: 
  • 1
    The article, Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: A meta-analysis, included eight randomized controlled studies involving 801 ADHF patients.
  • Data from the analysis demonstrated:
    UF was statistically better than diuretics in terms of increased fluid removal and weight loss.
  • Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.

CHF Solutions Continues Physician-Led Webinar Series with Focus on Treatment of Fluid Overload in Pediatric Patients

Retrieved on: 
Tuesday, July 14, 2020
Medicine, Clinical medicine, Branches of biology, Aquapheresis, Hypervolemia, Ultrafiltration, Intravascular volume status, RTT

MSPH shared his experience and perspectives on the treatment of fluid overload in pediatric patients weighing more than 20 kg.

Key Points: 
  • MSPH shared his experience and perspectives on the treatment of fluid overload in pediatric patients weighing more than 20 kg.
  • Addressing fluid overload and initiating treatment early optimizes outcomes in pediatric patients; therefore, fluid volume should be reported and monitored as a critical vital sign, similar to other vital signs.
  • To assess fluid overload, fluid volume status should be considered in light of the phases of therapy: rescue, optimization, stabilization and de-escalation.
  • Treatment options for fluid overload include medical management, fluid restriction and diuretics and ultrafiltration (aquapheresis).

CHF Solutions to Host Webinar Discussing Fluid Management Strategies in Critically Ill COVID-19 Patients

Retrieved on: 
Friday, June 12, 2020
Medicine, Anatomy, Branches of biology, Organ failure, Membrane technology, Renal physiology, Ultrafiltration, RTT, Kidney, Hypervolemia, Aquapheresis, Dialysis

When the kidneys cannot remove the excess fluid and waste in the body, these patients can experience kidney failure and multi-organ failure.

Key Points: 
  • When the kidneys cannot remove the excess fluid and waste in the body, these patients can experience kidney failure and multi-organ failure.
  • Effective fluid management in critically ill COVID patients can help prevent AKI and mitigate devastating outcomes in these patients.
  • Isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and management of fluid volume.
  • Portable ultrafiltration devices are proving particularly helpful in critically ill COVID-19 patients because the extremely small extracorporeal volume (i.e.

Publication Highlights Use of Ultrafiltration for Fluid Management in COVID-19 Patients

Retrieved on: 
Wednesday, May 20, 2020
Medicine, Branches of biology, Renal physiology, Ultrafiltration, Clinical medicine, Hypervolemia, Intravascular volume status, Membrane technology, Aquapheresis

EDEN PRAIRIE, Minn., May 20, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19.

Key Points: 
  • EDEN PRAIRIE, Minn., May 20, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19.
  • SARS-CoV-2 (COVID-19) and Intravascular Volume Management Strategies in the Critically Ill1 calls attention to fluid stewardship in COVID-19 patients by judiciously applying the evidence-based resuscitation principles to the specific clinical features of COVID-19 patients.
  • Highlights of ultrafiltration identified in the publication include:
    Isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and optimization of volume status;
    Portable ultrafiltration devices could prove particularly helpful because the extremely small extracorporeal volume (i.e.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.

CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management

Retrieved on: 
Wednesday, March 25, 2020
Health sciences, Health, Medicine, Hypervolemia, Ultrafiltration, Therapy, Aquapheresis

CHF Solutions expects increased demand for this ultrafiltration therapy as the rate of affected patients that are infected with COVID-19 is likely to increase.

Key Points: 
  • CHF Solutions expects increased demand for this ultrafiltration therapy as the rate of affected patients that are infected with COVID-19 is likely to increase.
  • We are pleased that we can help critical care patients during this time of need, said John Erb, CEO of CHF Solutions.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.
  • The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload).